全文获取类型
收费全文 | 18488篇 |
免费 | 986篇 |
国内免费 | 89篇 |
专业分类
耳鼻咽喉 | 204篇 |
儿科学 | 362篇 |
妇产科学 | 293篇 |
基础医学 | 2375篇 |
口腔科学 | 515篇 |
临床医学 | 1227篇 |
内科学 | 4672篇 |
皮肤病学 | 564篇 |
神经病学 | 1230篇 |
特种医学 | 741篇 |
外科学 | 2961篇 |
综合类 | 88篇 |
一般理论 | 2篇 |
预防医学 | 652篇 |
眼科学 | 273篇 |
药学 | 1409篇 |
中国医学 | 52篇 |
肿瘤学 | 1943篇 |
出版年
2023年 | 90篇 |
2021年 | 326篇 |
2020年 | 218篇 |
2019年 | 317篇 |
2018年 | 363篇 |
2017年 | 262篇 |
2016年 | 310篇 |
2015年 | 367篇 |
2014年 | 482篇 |
2013年 | 595篇 |
2012年 | 1005篇 |
2011年 | 1133篇 |
2010年 | 654篇 |
2009年 | 528篇 |
2008年 | 993篇 |
2007年 | 1020篇 |
2006年 | 1014篇 |
2005年 | 959篇 |
2004年 | 891篇 |
2003年 | 814篇 |
2002年 | 859篇 |
2001年 | 481篇 |
2000年 | 517篇 |
1999年 | 422篇 |
1998年 | 176篇 |
1997年 | 139篇 |
1996年 | 156篇 |
1995年 | 122篇 |
1994年 | 129篇 |
1993年 | 123篇 |
1992年 | 376篇 |
1991年 | 333篇 |
1990年 | 332篇 |
1989年 | 335篇 |
1988年 | 321篇 |
1987年 | 299篇 |
1986年 | 259篇 |
1985年 | 244篇 |
1984年 | 180篇 |
1983年 | 164篇 |
1981年 | 70篇 |
1979年 | 110篇 |
1978年 | 72篇 |
1977年 | 77篇 |
1974年 | 78篇 |
1973年 | 70篇 |
1972年 | 75篇 |
1971年 | 70篇 |
1970年 | 80篇 |
1969年 | 74篇 |
排序方式: 共有10000条查询结果,搜索用时 17 毫秒
1.
Iwasa-Inoue Naomi Nomura Hiroyuki Kataoka Fumio Chiyoda Tatsuyuki Yoshihama Tomoko Nanki Yoshiko Sakai Kensuke Kobayashi Yusuke Yamagami Wataru Morisada Tohru Hirasawa Akira Aoki Daisuke 《International journal of clinical oncology / Japan Society of Clinical Oncology》2022,27(2):441-447
International Journal of Clinical Oncology - This study aimed to investigate the clinical benefit of dose-dense paclitaxel plus carboplatin (TC) with bevacizumab therapy for advanced ovarian,... 相似文献
2.
Harada Hideyuki Omori Shota Mori Keita Konno Masahiro Murakami Haruyasu Imagumbai Toshiyuki Fukuda Haruyuki Nakamatsu Kiyoshi Kimura Tomoki Tanabe Hiroaki Fujita Hideki Tatebe Hitoshi Fujitaka Kazunori Nishimura Yasumasa 《International journal of clinical oncology / Japan Society of Clinical Oncology》2022,27(6):1025-1033
International Journal of Clinical Oncology - This multi-institutional clinical trial evaluated the feasibility of intensity-modulated radiotherapy (IMRT) for patients with locally advanced... 相似文献
3.
Kensuke Kudou Hiroshi Saeki Yuichiro Nakashima Shun Sasaki Tomoko Jogo Kosuke Hirose Qingjiang Hu Yasuo Tsuda Koichi Kimura Ryota Nakanishi Nobuhide Kubo Koji Ando Eiji Oki Tetsuo Ikeda Yoshihiko Maehara 《American journal of surgery》2019,217(4):757-763
Background
There were few studies assessed the postoperative sarcopenia in patients with cancers. The objective of present study was to assess whether postoperative development of sarcopenia could predict a poor prognosis in patients with adenocarcinoma of esophagogastric junction, (AEG) and upper gastric cancer (UGC).Methods
Patients with AEG and UGC who were judged as non-sarcopenic before surgery were reassessed the presence of postoperative development of sarcopenia 6 months after surgery. Patients were divided into the development group or non-development group, and clinicopathological factors and prognosis between these two groups were analyzed.Results
The 5-year overall survival rates were significantly poorer in the development group than non-development group (68.0% vs. 92.6%, P?=?0.0118). Multivariate analyses showed that postoperative development of sarcopenia was an independent prognostic factor for poor overall survival (P?=?0.0237).Conclusions
Postoperative development of sarcopenia was associated with a poor prognosis in patients with AEG and UGC. 相似文献4.
5.
6.
Tetsuo Mitsui Naoto Fujita Yuhki Koga Reiji Fukano Tomoo Osumi Asahito Hama Katsuyoshi Koh Harumi Kakuda Masami Inoue Takahiro Fukuda Hiromasa Yabe Junko Takita Akira Shimada Yoshiko Hashii Atsushi Sato Yoshiko Atsuta Yoshinobu Kanda Junji Suzumiya Ryoji Kobayashi 《Pediatric blood & cancer》2020,67(4)
7.
Yusuke Kagawa Hiromi Furuta Takehiro Uemura Naohiro Watanabe Junichi Shimizu Yoshitsugu Horio Hiroaki Kuroda Yoshitaka Inaba Takeshi Kodaira Katsuhiro Masago Shiro Fujita Akio Niimi Toyoaki Hida 《Cancer science》2020,111(12):4442
Immune checkpoint inhibitors (ICIs) have dramatically changed the strategy used to treat patients with non‐small‐cell lung cancer (NSCLC); however, the vast majority of patients eventually develop progressive disease (PD) and acquire resistance to ICIs. Some patients experience oligoprogressive disease. Few retrospective studies have evaluated clinical efficacy in patients with oligometastatic progression who received local therapy after ICI treatment. We conducted a retrospective analysis of advanced NSCLC patients who received PD‐1 inhibitor monotherapy with nivolumab or pembrolizumab to evaluate the effects of ICIs on the patterns of progression and the efficacy of local therapy for oligoprogressive disease. Of the 307 patients treated with ICIs, 148 were evaluated in our study; 42 were treated with pembrolizumab, and 106 were treated with nivolumab. Thirty‐eight patients showed oligoprogression. Male sex, a lack of driver mutations, and smoking history were significantly correlated with the risk of oligoprogression. Primary lesions were most frequently detected at oligoprogression sites (15 patients), and 6 patients experienced abdominal lymph node (LN) oligoprogression. Four patients showed evidence of new abdominal LN oligometastases. There was no significant difference in overall survival (OS) between the local therapy group and the switch therapy group (reached vs. not reached, P = .456). We summarized clinical data on the response of oligoprogressive NSCLC to ICI therapy. The results may help to elucidate the causes of ICI resistance and indicate that the use of local therapy as the initial treatment in this setting is feasible treatment option. 相似文献
8.
9.
Eo Toriyama Tomoko Hata Kenichi Yokota Masahiko Chiwata Rena Kamijo Miki Hashimoto Masataka Taguchi Makiko Horai Masatoshi Matsuo Emi Matsuo Yumi Takasaki Yasuhisa Kawaguchi Hidehiro Itonaga Shinya Sato Koji Ando Yasushi Sawayama Jun Taguchi Yoshitaka Imaizumi Hideki Tsushima Tatsuro Jo Shinichiro Yoshida Yukiyoshi Moriuchi Yasushi Miyazaki 《Cancer science》2020,111(12):4490
The efficacy of azacitidine (AZA) on survival of lower risk (LR) ‐ myelodysplastic syndromes (MDS) is controversial. To address this issue, we retrospectively evaluated the long‐term survival benefit of AZA for patients with LR‐MDS defined by International Prognostic Scoring System (IPSS). Using data from 489 patients with LR‐MDS in Nagasaki, hematologic responses according to International Working Group 2006 and overall survival (OS) were compared among patients that received best supportive care (BSC), immunosuppressive therapy (IST), erythropoiesis‐stimulating agents (ESA), and AZA. Patients treated with AZA showed complete remission (CR) rate at 11.3%, marrow CR at 1.9%, and any hematologic improvement at 34.0%, with transfusion independence (TI) of red blood cells in 27.3% of patients. and platelet in 20% of patients, respectively. Median OS for patients received IST, ESA, BSC, and AZA (not reached, 91 months, 58 months, and 29 months, respectively) differed significantly (P < .001). Infection‐related severe adverse events were observed in more than 20% of patients treated with AZA. Multivariate analysis showed age, sex, IPSS score at diagnosis, and transfusion dependence were significant for OS, but AZA treatment was not, which maintained even response to AZA, and IPSS risk status at AZA administration was added as factors. We could not find significant survival benefit of AZA treatment for LR‐MDS patients. 相似文献